ANDA 204097, held by Hetero Labs. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 204097 (Children's Fexofenadine Hydrochloride Allergy, Fexofenadine Hydrochloride Allergy), held by Hetero Labs, was first approved by FDA on Aug 19, 2016, with 0 approved supplements and 0 published complete response letters.
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2016 | Original application | Approved | None posted |
| Children's Fexofenadine Hydrochloride Allergy30MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters